XERS - Company ID 0001867096
The table below shows Xeris Biopharma Holdings, Inc.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $291.85M | $203.07M | $163.91M | $110.25M | $49.59M | $20.43M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $31.16M | $25.56M | $22.34M | $20.97M | $25.16M | $20.92M |
| SG&A |
Xeris Biopharma Holdings, Inc. reported annual revenue of $291.85M for fiscal year 2025. That is up 43.7% from $203.07M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $20.43M (FY 2020) to $291.85M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $182.37M |
| $163.48M |
| $146.09M |
| $137.75M |
| $125.72M |
| $73.73M |
| Operating income | $24.90M | -$33.65M | -$44.01M | -$81.94M | -$115.16M | -$83.55M |
| Income tax | $0.00 | -$2.27M | -$1.25M | -$1.42M | $0.00 | -$110.00K |
| Net income | $554.00K | -$54.84M | -$62.26M | -$94.66M | -$122.72M | -$91.14M |
| EPS (diluted) | $0.00 | -$0.37 | -$0.45 | -$0.70 | -$1.55 | - |